データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
59989-18-3C#Cc1c[nH]c(=O)[nH]c1=OJOZGNYDSEBIJDH-UHFFFAOYSA-N59989-18-3DTXSID10208696CHEMBL355200CHEBI:177783安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
使用Potent inactivator of Dihydropyrimidine dehydrogenase (DPD).
読み込み中…